Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) insider Shiv O'neill bought 3,998 shares of the company's stock in a transaction dated Tuesday, August 18th. The stock was bought at an average cost of $23.58 per share, with a total value of $94,272.84. Following the completion of the acquisition, the insider owned 87,832 shares in the company, valued at $2,071,078.56. This represents a 4.77% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Elanco Animal Health Price Performance
Elanco Animal Health stock opened at $23.63 on Wednesday. The business has a 50 day simple moving average of $24.54 and a 200 day simple moving average of $24.01. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The company has a market capitalization of $11.80 billion, a PE ratio of -57.63, a price-to-earnings-growth ratio of 1.42 and a beta of 1.67. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.31 billion. During the same period in the prior year, the business posted $0.26 earnings per share. The business's revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on ELAN. JPMorgan Chase & Co. lifted their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, May 7th. Morgan Stanley raised their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 22nd. Wall Street Zen cut shares of Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Sunday, May 24th. TD Cowen lifted their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, June 18th. Finally, Weiss Ratings raised Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.09.
Check Out Our Latest Analysis on ELAN
Institutional Trading of Elanco Animal Health
Several hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio grew its stake in shares of Elanco Animal Health by 113.0% during the second quarter. Public Employees Retirement System of Ohio now owns 330,645 shares of the company's stock valued at $8,137,000 after purchasing an additional 175,412 shares during the last quarter. Proficio Capital Partners LLC bought a new position in Elanco Animal Health in the 2nd quarter worth approximately $260,000. Corient Private Wealth LP acquired a new position in Elanco Animal Health during the 2nd quarter worth $8,565,000. Park West Asset Management LLC acquired a new position in Elanco Animal Health during the 2nd quarter worth $24,979,000. Finally, Bank of America Corp DE boosted its position in Elanco Animal Health by 16.4% in the 2nd quarter. Bank of America Corp DE now owns 3,909,871 shares of the company's stock valued at $96,222,000 after buying an additional 551,656 shares during the last quarter. 97.48% of the stock is owned by institutional investors.
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
